Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next
mRNA vaccines represent a promising immunotherapy for prostate cancer, demonstrating early clinical activity in trials such as CV9104 and showing potential for personalized treatment when combined with immune‑modulating strategies.
Prostate cancer (PC) treatment is evolving beyond conventional therapies. This review explores mRNA‑based vaccines as a promising immunotherapy. We discuss their mechanism of action, advantages in production and safety, and results from early clinical trials (e.g., CV9103/4). Key challenges like antigen selection and the immunosuppressive tumour microenvironment are addressed, alongside advancements in lipid nanoparticle delivery and combinatorial strategies with checkpoint inhibitors to enhance efficacy and usher in personalised PC treatment.
Prostate cancer remains a leading cause of male cancer mortality and often progresses to metastatic castration‑resistant disease with limited treatment options and rapid development of resistance. New Igore‑based immunotherapies must overcome a quiescent tumour microenvironment and antigenic heterogeneity to improve survival.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience